StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Questions for this Presentation

<< Previous

Bullboard Posts

Next >>

Post by johnny007on Apr 22, 2021 8:55am

244 Views

Post# 33043443

Questions for this Presentation

Not going into to deep into details, but I like the following to be addressed.

(a1) Is there a shareholder vote on the merger with Health Clinic, widening Stage Zero's focus into treating cancer?

(a2) Will you disclose the financial details of this company?

(a3) What are their annual operating income or cash used?

(b1) How do you compare Aristotle specificity with competitors?
Is around 10% potential false positive acceptable in the market?

<< Previous

Bullboard Posts

Next >>

Soma Gold poised to extend profitable track record